Rebecca Nunn 2/1/22 Rebecca Nunn 2/1/22

Aqualung Therapeutic’s ALT-100 Antibody Significantly Reduces ARDS Severity in Both Rat and Porcine (Large Animal) Preclinical Models

Aqualung Therapeutic’s ALT-100 Antibody Significantly Reduces ARDS Severity in Both Rat and Porcine (Large Animal) Preclinical Models ByACCESSWIRE Published February 1,

Rebecca Nunn 1/18/22 Rebecca Nunn 1/18/22

Aqualung Therapeutics Corp., an Immunotherapeutics Biotech Company, Closes a $2.5M Convertible Note Raise With a Committed Series A Lead Investor

Aqualung Therapeutics Corp., an Immunotherapeutics Biotech Company, Closes a $2.5M Convertible Note Raise With a Committed Series A Lead Investor Tuesday,

Rebecca Nunn 12/7/21 Rebecca Nunn 12/7/21

CEO & Founder of Aqualung Therapeutics Corp., Joe G.N. Garcia MD to Present Corporate Update at the Annual Biotech Showcase in San Francisco

CEO & Founder of Aqualung Therapeutics Corp., Joe G.N. Garcia MD to Present Corporate Update at the Annual Biotech

Rebecca Nunn 8/26/21 Rebecca Nunn 8/26/21

Aqualung Therapeutics Selected to Present at the Phoenix 2021 Venture Madness Competition on October 6-7th

Rebecca Nunn 7/22/21 Rebecca Nunn 7/22/21

Dr. Garcia Grand Rounds at Houston Methodist: A Systems Biology Journey to DAMPen Acute Lung Inflammation

Rebecca Nunn 6/15/21 Rebecca Nunn 6/15/21

Aqualung Therapeutics Plans A Phase 0 ARDS Trial for eNAMPT Monoclonal Antibody (Alt-100 mAb) Following Type B FDA Meeting

Aqualung Therapeutics Plans A Phase 0 ARDS Trial for eNAMPT Monoclonal Antibody (Alt-100 mAb) Following Type B FDA Meeting Phase 0

Rebecca Nunn 6/3/21 Rebecca Nunn 6/3/21

CEO of Aqualung Therapeutics Corp., Joe G.N. Garcia MD, Named Invited Speaker at the First Annual Acute Respiratory Distress Syndrome Drug Development Summit

CEO Of Aqualung Therapeutics Corp., Joe G.N. Garcia MD, Named Invited Speaker at the First Annual Acute Respiratory Distress Syndrome Drug

Rebecca Nunn 2/15/21 Rebecca Nunn 2/15/21

Studies: eNAMPT, an inflammation-regulatory protein is now tightly linked to COVID-19 deaths

Studies: eNAMPT, an inflammation-regulatory protein is now tightly linked to COVID-19 deaths LINK TO FULL ARTICLE 2.13.21 Studies: eNAMPT, an inflammation-regulatory protein is now tightly

Rebecca Nunn 2/11/21 Rebecca Nunn 2/11/21

eNAMPT, the Inflammation-Regulatory Protein Specifically Targeted by Aqualung Therapeutic’s Monoclonal Antibody ALT-100, is now Tightly Linked to Outcomes in COVID-19 Infected Patients

eNAMPT, the Inflammation-Regulatory Protein Specifically Targeted by Aqualung Therapeutic’s Monoclonal Antibody ALT-100, is now Tightly Linked to Outcomes in COVID-19 Infected Patients LINK TO PRESS

Rebecca Nunn 12/2/20 Rebecca Nunn 12/2/20

Aqualung Therapeutics Corp. Publication Supports eNAMPT as Both Biomarker & Therapeutic Target in Prostate Cancer; Prostate Cancer KOL New Addition to Scientific Advisory Board

READ PRESS RELEASE 12.2.20 Aqualung Therapeutics Corp. Publication Supports eNAMPT as Both Biomarker & Therapeutic Target in Prostate Cancer; Prostate Cancer KOL New Addition to

Rebecca Nunn 9/22/20 Rebecca Nunn 9/22/20

Aqualung Therapeutics Corp. Awarded $300 Thousand From National Institute of Health (NIH) to Develop a Novel Therapeutic for Pregnant Women at Risk for Preterm Births

Aqualung Therapeutics Corp. Awarded $300 Thousand From National Institute of Health (NIH) to Develop a Novel Therapeutic for Pregnant Women at